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Abstract
GWAS, immune analyses and biomarker screenings have identified host factors associated
with in vivo HIV-1 control. However, there is a gap in the knowledge about the mechanisms
that regulate the expression of such host factors. Here, we aimed to assess DNA methyla-
tion impact on host genome in natural HIV-1 control. To this end, whole DNA methylome in
70 untreated HIV-1 infected individuals with either high (>50,000 HIV-1-RNA copies/ml, n =
29) or low (<10,000 HIV-1-RNA copies/ml, n = 41) plasma viral load (pVL) levels were com-
pared and identified 2,649 differentially methylated positions (DMPs). Of these, a classifica-
tion random forest model selected 55 DMPs that correlated with virologic (pVL and proviral
levels) and HIV-1 specific adaptive immunity parameters (IFNg-T cell responses and neu-
tralizing antibodies capacity). Then, cluster and functional analyses identified two DMP
clusters: cluster 1 contained hypo-methylated genes involved in antiviral and interferon
response (e.g. PARP9, MX1, and USP18) in individuals with high viral loads while in cluster
2, genes related to T follicular helper cell (Tfh) commitment (e.g. CXCR5 and TCF7) were
hyper-methylated in the same group of individuals with uncontrolled infection. For selected
genes, mRNA levels negatively correlated with DNA methylation, confirming an epigenetic
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regulation of gene expression. Further, these gene expression signatures were also con-
firmed in early and chronic stages of infection, including untreated, cART treated and elite
controllers HIV-1 infected individuals (n = 37). These data provide the first evidence that
host genes critically involved in immune control of the virus are under methylation regulation
in HIV-1 infection. These insights may offer new opportunities to identify novel mechanisms
of in vivo virus control and may prove crucial for the development of future therapeutic inter-
ventions aimed at HIV-1 cure.
Author summary
The infection with the human immunodeficiency virus (HIV), as for other viral infections,
induce global DNA Methylation changes in the host genome. Herein, we identified for
first time the methylation impact on host genome in untreated HIV-1 infection with dif-
ferent degrees of in vivo virus control. Specifically, we observed that individuals with a bet-
ter HIV-1 control showed a hypermethylation of genes associated with antiviral and
interferon pathways and the hypomethylation of genes associated with the differentiation
process of T follicular helper cells. Interestingly, these epigenetic imprints in host genome
were strongly correlated with virus content and HIV-specific T cell responses. Therefore,
we propose DNA Methylation as the regulation mechanism of host genes involved in
immune HIV-1 control that could interfere in the efficacy of cure strategies. We also high-
light the importance of DNA Methylation to regulate immune responses not only in HIV-
1 but also in chronic infections or other pathologic situations associated with a sustained
activation of the immune system.
Introduction
Treatment of HIV-1 infected individuals with antiretroviral drugs (combination antiretroviral
therapy, cART) is highly effective in suppressing viral replication to undetectable levels. How-
ever, the virus persists in the body in form of a proviral reservoir in latently infected cells and
cART needs therefore to be taken for life. Given that the access and adherence to the treatment
might be limited, especially in low-income countries and considering the health consequences
of long-term cART use, stigma and high costs, there is a need for the development of new strat-
egies to achieve a so-called functional cure and/or interventions that can eliminate the virus
from the body [1]. The study of the small-subset of HIV-1 controllers, i.e. HIV-1-infected peo-
ple that can naturally maintain undetectable or low HIV-1 plasma viral load (pVL) without
cART, have been of relevance to understand the mechanisms of spontaneous HIV-1 viral con-
trol [2]. Such control has been mainly linked to host factors, especially HLA genetics and anti-
viral immunity mediated by HIV-1-specific CD8 and CD4 T-cells, as well as to virological
factors including viral mutations that reduce viral replicative fitness [3]. Despite this progress,
there remain significant gaps in the understanding of spontaneous virus control and how the
maintenance of HIV-1 latency can be broken [4,5].
For several viral infections, different epigenetic changes have been described in the
genomes of both, the virus and the host [6]. Some of these epigenetic changes, in particular
DNA methylation of genes, can be induced upon initial infection. The process is driven mainly
by the increase of DNA Methyltransferases (DNMT), the enzymes that catalyze the transfer of
methyl groups to cytosine residues of DNA. At the level of viral DNA, several reports have
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suggested that the hypermethylation of 5’LTR regions of HIV-1 proviral is of relevance for
latency maintenance [7]. In contrast, for methylation changes of host genes, most reports to
date have assessed methylation levels of single host genes and only a few studies exist that deter-
mined DNA methylation of whole host genomes in HIV-1 infection [8–10]. Among these, the
analysis of PBMC DNA methylation patterns in a pair of monozygotic twins sero-discordant
for HIV-1 infection, revealed an overall increase in host DNA methylation in the HIV-1
infected compared to the HIV-1 uninfected twin [10]. A subsequent study that assessed differ-
ential DNA methylation patterns between HIV-1 infected and uninfected individuals, identified
altered epigenetic regulation of host factors such as NLRC5 and LPCAT1 [9]. These studies indi-
cate that HIV-1 infection may leave marked changes in the host DNA methylation patterns that
could affect the expression of host factors involved in viral replication as well as in innate and
adaptive immune defense. In light of ongoing efforts to restore effective antiviral immunity and
achieve sustained functional cure of HIV-1 infection, it will be critical to i) identify such methyl-
ation-dependent epigenetic imprints in HIV-1 infection, ii) understand their effects on antiviral
immunity and importantly, iii) find ways to not only transiently restore antiviral immune
responses but to correct their underlying epigenetic dysregulation to achieve lasting cure [11].
In this report, full host-genome DNA methylation analysis in a cohort of HIV-1 infected
individuals with variable ability to spontaneously control viral replication in vivo, reveal for
the first time, key methylation signatures in peripheral blood predictive of HIV-1 plasma viral
loads and proviral levels, as well as HIV-1-specific adaptive immunity, associated with natural
HIV-1 control. Therefore, these data strongly support an important role of epigenetics as a reg-
ulation mechanism behind HIV-1 control that should be considered in future therapeutic
strategies.
Results
Differential DNA methylation patterns in PBMC of untreated HIV-1
chronically infected individuals with variable levels of HIV-1 pVL
With the aim of determining DNA methylation patterns that could be predictive of viral con-
trol, PBMC isolated from 70 HIV-1 infected individuals were subjected to a genome-wide
DNA methylation analysis. This cohort included a group of subjects with high (HIV-High;
pVL>50,000 HIV-1 RNA copies/ml, n = 29) or low HIV-1 viral loads (HIV-Low; pVL
<10,000 HIV-1 RNA copies/ml, n = 41).
After a pre-processing step (Fig 1A), 56,513 CpG positions were left to be analyzed for
methylation differences between the two groups. A previously described linear model-based
approach that adjusts for methylation confounders (including sex, age and estimated cell type
proportion [9,12]) was combined with a correction for individuals´ CD4 counts due to the sig-
nificant differences between both groups for this parameter. This analysis identified a total of
3,671 differentially methylated positions (DMPs) considering a p-value < 0.05 as cut-off (Fig
1A). Only the DMPs between both groups of HIV-1 infected individuals that had a gene anno-
tation (n = 2,649) were kept for further analyses. Of them, n = 1,668 (63%) were found in CpG
Islands (CGIs) regions: including 29% in the island itself, 27.5% in CpG shores (2Kb from
CGI), and 6.5% in CpG shelves (4 Kb from CGI). A total of n = 1,536 (58%) of DMP were
localized in promoter regions of the genes (including TSS1500, TSS200, 5’UTR and 1st Exon
regions), suggestive of a potential effect on gene expression levels [13]. Fig 1B shows 224 CpG
positions hypomethylated (blue) and 910, hypermethylated (red) in HIV-High individuals.
Overall, DMPs were widely distributed across the whole genome, with chromosomes 3, 11, 12
and 16 containing the highest number of DMPs relative to the number of analyzed CpG posi-
tions per chromosome (Chi-squared test, p< 0.05, Fig 1C). These data highlight that there
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exist distinct DNA methylation patterns widely distributed across the entire host genome that
differentiate chronically HIV-1 infected individuals with spontaneous high or low pVL.
Relative control of in vivo HIV-1 replication is associated with DMPs in
gene encoding proteins involved in adaptive and innate immune responses
To select differentially methylated positions (DMPs) that could discriminate between individ-
uals with high or low HIV-1 pVL and to be used in downstream analyses, we applied a random
Fig 1. Differentially methylated CpG positions between HIV-1 infected patients with different ranges of plasma viral loads. (A) Analysis strategy for the
identification of differentially methylated positions (DMPs). (B) Volcano Plot showing 2,649 gene annotated DMPs (p-value is shown in Y-axis and the
regression coefficient from de model on the X-axis). Blue indicates hypomethylation and red, hypermethylation in HIV-High group. Labels indicate top 9 CpG
sites with a coefficient higher than |0.1| in HIV-High or HIV-Low. (C) The Manhattan Plot shows the identified DMPs, according the log2 Fold-Change (FC) (Y-
axis) and their location on different chromosomes (X-axis).
https://doi.org/10.1371/journal.ppat.1008678.g001
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forest model with 1000 iterations and 5-fold cross-validations [14,15] on the 2,649 gene anno-
tated DMPs (AUC = 0.92). This resulted in the identification of 55 DMPs, of which 26 (47%)
were located in CpG islands of promoter regions (Table 1). The most selected DMP,
cg22930808, is located in the promoter of PARP9-DTX3L gene on chromosome 3 (hyper-
methylated in HIV-Low, Table 1).
The selected 55 DMPs clustered in two different groups that differentiate HIV-Low from
HIV-High individuals (Table 1 and Fig 2A and 2B): Cluster 1 (Fig 2A) included 31 DMPs
hypermethylated in HIV-Low individuals and cluster 2 (Fig 2B), included 24 DMPs hypo-
methylated in this same group. Gene ontology enrichment analysis (GEA) showed (Fig 2C and
2D, S3 Table) cluster 1 to be enriched for gene ontology (GO) categories involved in antiviral
activity such as defense response to virus (GO:0051607, 6 genes), type I interferon signaling
pathway (GO:0060337, 3 genes), or regulation of innate immune response (GO:0045088, 5
genes). In contrast, cluster 2 was represented by general immune activation GO categories
including leukocyte activation (GO:0045321, 6 genes), T cell activation (GO:0042110, 4 genes),
T cell differentiation (GO:0030217, 3 genes) or positive regulation of protein modification pro-
cess (GO:0031401, 5 genes).
Overall, these data reinforce that the identified epigenetically regulated immune pathways
of antiviral activity and innate immune activation are associated with HIV-1 pVL in the
peripheral blood. Taken together, different levels of in vivo virus control are associated with
markedly different methylation patterns of genes involved in antiviral innate and cellular
adaptive host defense mechanisms.
Differential methylation patterns are associated with proviral levels and
markers of adaptive host immunity to HIV-1
To determine whether the DMPs associated with additional immune and virological markers
beyond pVL, we correlated the methylation levels of the 55 DMPs identified above with provi-
ral (total HIV-1 DNA) in PBMC lysates and extensive immune data, including measurements
of cellular and humoral immunity to HIV-1 (S1 Table). T cell responses were determined by
IFNg ELISpot assay against overlapping peptides of the entire consensus B HIV-1 proteome,
and levels of neutralizing Ab (nAb) in plasma were determined against the HIV-1 BaL labora-
tory adapted strain. Table 2 shows the correlation data (Rho values, p<0.05, Spearman’s rank
correlation test) between the relevant CpG positions contained in the two clusters and the dif-
ferent virological or immune parameters assessed.
DMPs in cluster 1, related to antiviral defense and innate immunity, showed the highest
correlations with HIV-1 pVL and proviral levels. Specifically, the DMPs with the strongest cor-
relations were the ones in the promoter regions of the PARP9-DTXL3 (cg22930808 and
cg08122652) and ODF3B genes (cg20098015, cg23221113 and cg11224765) that were also the
most frequently selected in the random forest model (Table 2). The PARP9 CpG positions
were also correlated with the rest of variables measured, including levels of HIV-1 specific T-
cells and nAb activity. Interestingly, in the same antiviral response group, PARP9 (Fig 2B) clus-
tered together with DMPs in MX1 (cg22862003), IRF7 (cg08926253), PLSCR1 (cg06981309),
USP18 (cg14293575) and IFI44L (cg06872964), all genes which were also correlated with HIV-
1 pVL and proviral (Table 2). Additionally, the methylation levels of the CpG positions in
MX1, IRF7 and PLSCR1 were related to the magnitude and breadth of the HIV-1-specific T-
cell immune responses (Table 2). With the exception of USP18, all these genes were annotated
in the functional category response to virus (GO:0009615) and immune effector processes
(GO:0002252) among others (S3 Table). In addition, USP18 was annotated together with
MX1, IRF7 and PARP9 in the functional category of genes involved in the regulation of defense
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Table 1. Classificatory CpG positions into the groups of HIV-High or HIV-Low.
CpG
position
Gene Chr Relation to
Island












cg22930808 PARP9_DTX3L chr3 N_Shore 5UTR_TSS1500 0.76 0.56 0.02 821 1 #
cg20098015 ODF3B chr22 S_Shore TSS200 0.64 0.5 0.05 724 1 #
cg01028142 CMPK2 chr2 N_Shore Body 0.88 0.8 <0.01 643 1 -
cg23221113 ODF3B chr22 S_Shore 5UTR_1stExon 0.29 0.22 0.02 613 1 #
cg20939114 PITPNC1 chr17 OpenSea Body 0.26 0.33 0.02 607 2 -
cg10152449 CHST12 chr7 S_Shore 5UTR 0.56 0.41 0.05 458 1 #
cg02217713 PRKAR1B chr7 N_Shore Body 0.71 0.62 0.05 452 1 -
cg08122652 PARP9_DTX3L chr3 N_Shore 5UTR_TSS1500 0.77 0.6 0.02 430 1 #
cg02538772 SND1 chr7 OpenSea Body 0.57 0.64 0.04 374 2 "
cg15413523 TCF7 chr5 S_Shore 5UTR_1stExon 0.47 0.54 0.04 308 2 "
cg20651018 CARS chr11 OpenSea Body 0.52 0.64 0.02 308 2 -
cg14392283 LY6E chr8 N_Shelf 3UTR 0.84 0.76 0.02 301 1 -
cg13015616 HFE chr6 OpenSea TSS1500 0.61 0.71 0.03 264 2 "
cg26005232 NUDC chr1 N_Shore TSS1500 0.48 0.56 0.04 240 2 "
cg11224765 ODF3B chr22 S_Shore TSS200 0.58 0.48 0.01 231 1 #
cg08863939 TLK1 chr2 OpenSea 5UTR 0.46 0.55 0.04 225 2 "
cg08926253 IRF7 chr11 Island Body 0.74 0.66 0.01 225 1 -
cg21535657 ETV6 chr12 S_Shelf Body 0.32 0.25 0.01 168 1 -
cg04537602 CXCR5 chr11 OpenSea Body_TSS1500 0.53 0.63 0.05 154 2 "
cg02679745 C9orf139_FUT7 chr9 S_Shore Body_TSS1500 0.64 0.56 0.03 148 1 #
cg11477010 ANKFY1 chr17 OpenSea Body 0.67 0.73 0.01 141 2 -
cg01190666 PRIC285 chr20 N_Shore 5UTR 0.72 0.66 0.02 126 1 #
cg22862003 MX1 chr21 N_Shore TSS1500_5UTR 0.75 0.62 0.05 124 1 #
cg06981309 PLSCR1 chr3 N_Shore 5UTR 0.75 0.62 0.02 107 1 #
cg02297838 MIR19A_MIR17HG chr13 S_Shore TSS1500_Body 0.52 0.4 0.02 106 1 #
cg01774027 ARID3A chr19 Island Body 0.6 0.52 0.02 95 1 -
cg20631044 C19orf54_SNRPA chr19 N_Shore TSS200_TSS1500 0.68 0.61 0.03 95 1 #
cg18338046 TCF7 chr5 S_Shore Body 0.58 0.69 <0.01 90 2 -
cg01623438 CTSZ chr20 S_Shore TSS1500 0.66 0.6 0.01 89 1 #
cg14293575 USP18 chr22 S_Shelf 5UTR 0.72 0.6 0.03 78 1 #
cg06164260 BCL6 chr3 N_Shore 5UTR_TSS200 0.61 0.55 0.01 76 1 #
cg19400179 DZIP3 chr3 OpenSea 5UTR 0.37 0.47 0.03 70 2 "
cg02676052 LCP2 chr5 OpenSea TSS1500 0.62 0.67 0.02 69 2 "
cg14191134 LOC283050 chr10 S_Shore Body 0.37 0.3 0.05 68 1 -
cg21549285 MX1 chr21 S_Shore 5UTR 0.77 0.61 0.01 67 1 #
cg00808969 USP35_KCTD21 chr11 N_Shore TSS1500_5UTR 0.41 0.48 0.01 66 2 "
cg13298528 CXCR5 chr11 OpenSea Body_TSS1500 0.57 0.67 0.04 60 2 "
cg15065340 TNK2 chr3 N_Shelf 5UTR 0.7 0.62 0.03 58 1 #
cg05883128 DDX60 chr4 N_Shore 5UTR 0.48 0.37 0.04 45 1 #
cg19368911 KIF26B chr1 OpenSea Body 0.5 0.58 0.05 45 2 -
cg00688810 SHBG_FXR2 chr17 N_Shore TSS1500_Body 0.72 0.78 0.04 43 2 "
cg03043696 GNB1 chr1 N_Shore 5UTR 0.61 0.55 0 43 1 #
cg10435235 ARHGEF7 chr13 OpenSea 3UTR 0.74 0.69 0.03 42 1 -
cg27519392 CHD7 chr8 OpenSea Body 0.63 0.71 0.03 40 2 -
cg26567688 COL4A3BP chr5 OpenSea Body 0.67 0.74 0.05 29 2 -
cg08179431 HFE chr6 OpenSea TSS1500 0.7 0.79 0.03 27 2 "
(Continued)
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response (GO:0031347) and, with MX1 and IRF7, in the category response to type I interferon
(GO:0034340).
Similarly, in cluster 2, the DMP in the body of the CARS gene (cg20651018) was correlated
with measured viral parameters and levels of HIV-1 specific T cell responses (Table 2). Fur-
thermore, DMPs in promoter region of the HFE gene (cg13015616 and cg08179431) correlated
with HIV-1 pVL, proviral levels, and breadth and magnitude of the virus-specific T cell
responses. The HFE gene is involved in general T cell activation [16,17] and, interestingly,
both DMPs showed the strongest correlation with other DMPs in the circle plot (S1 Fig). In
addition, DMPs in the genes CXCR5 (cg04537602 and cg13298528) and TCF7 (cg15413523
cg18338046), both falling into the categories of lymphocyte and T-cell activation (GO:0046649
lymphocyte activation, GO:0046631 alpha-beta T-cell activation, GO:0042110 T-cell activation
or GO:0030217 T-cell differentiation), were all correlated with the breadth and magnitude of
the virus-specific T-cell response, as well as with pVL and proviral levels (Table 2). Overall,
these correlation analyses highlight the potential relevance of epigenetic regulation of PARP9,
MX1, IRF7, USP18, PLSCR1 and IFI44L genes from cluster 1 (innate/antiviral response) and
HFE, CXCR5 and TCF7 genes from cluster 2 (T-cell activation) in determining levels of viro-
logic parameters, HIV-specific T cell responses and in vivo virus control.
Methylation levels of candidate genes translate inversely into different
mRNA levels
To demonstrate a direct relationship between methylation levels and gene expression activity,
we determined transcription levels for selected candidates. The top signals emerging from the
random forest list (Table 1) included DMPs in promoters of genes PARP9/DTX3L and
ODF3B, among others. Of importance, PARP9/DTX3L DMPs (cg22930808 and cg08122652)
were strongly correlated with pVL and proviral (Table 2) and were included in the cluster
enriched by antiviral gene ontology terms (Fig 2A and 2C). Focusing on that cluster 1, PARP9
was in turn correlated with MX1, PLSCR1, IFI44L and USP18. Gene expression was assessed
for PARP9, MX1 and USP18 using available total PBMC samples from the same individuals




Gene Chr Relation to
Island












cg12042587 GHR chr5 N_Shore TSS200 0.22 0.28 0.01 27 2 "
cg22036538 CD27_LOC678655 chr12 OpenSea 1stExon_5UTR 0.34 0.44 0.02 27 2 "
cg20321801 CD81 chr11 N_Shelf Body 0.59 0.53 0.01 27 1 -
cg04858110 SCRN1 chr7 OpenSea 5UTR_Body 0.66 0.72 0.04 24 2 "
cg12217560 TNFRSF19 chr13 OpenSea 1stExon_5UTR 0.51 0.58 0.04 21 2 "
cg06872964 IFI44L chr1 OpenSea TSS1500 0.7 0.59 0.02 19 1 #
cg07892167 R3HCC1 chr8 N_Shore TSS1500 0.52 0.45 0.04 17 1 #
cg14659511 DOCK9 chr13 OpenSea Body 0.62 0.69 0.01 14 2 -
cg02385820 RINL chr19 N_Shore 3UTR 0.71 0.67 <0.01 13 1 -
A p-value of the regression model applied to determine DMPs.
B CpG positions ordered according the frequency of selection by random forest model.
C For CpGs in promoters, it is shown the expected gene expression in case of an epigenetic regulation. Values are relative to HIV-Low group.
Chr = Chromosome.
https://doi.org/10.1371/journal.ppat.1008678.t001
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Fig 2. Relevant DMPs for classification in HIV-High and HIV-Low groups. Cluster analyses of the selected CpG positions for the classification of individuals
(random forest model). Two clusters are showed in A and B as heatmaps that differentiate HIV-Low from HIV-High subjects. Distances are based on Manhattan
and clustering, on complete linkage. Columns represent tested individuals, HIV-High (blue) and HIV-Low (green), and rows depict the Beta-values of the CpGs
in each cluster. The colour scale from red to yellow represents from low to high methylation. (C-D) Histogram plots of the Gene Ontology Enrichment Analysis
(clusterProfiler R/Bioconductor) for the two identified clusters (A and B) of DMPs. Pathways with the highest significance are shown; the complete output is in
S3 Table.
https://doi.org/10.1371/journal.ppat.1008678.g002
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Table 2. CpG positions correlation with virological and immunological parameters.





Proviral DNA CD4 Counts CTL Breadth CTL Magnitude nAb BaL
Rho p-value Rho p-value Rho p-value Rho p-value Rho p-value Rho p-value
cg22930808 PARP9
DTX3L
1 821 -0.73 9.39E-13 -0.59 2.20E-06 0.59 7.47E-08 0.36 4.09E-03 0.37 2.62E-03 -0.43 9.34E-04
cg20098015 ODF3B 1 724 -0.69 4.86E-11 -0.51 7.45E-05 0.53 2.36E-06 0.32 1.14E-02 0.34 6.17E-03 - -
cg01028142 CMPK2 1 643 -0.61 1.53E-08 -0.46 4.79E-04 0.47 4.14E-05 - - 0.29 2.00E-02 - -
cg23221113 ODF3B 1 613 -0.74 3.87E-13 -0.56 8.55E-06 0.52 4.87E-06 0.37 2.63E-03 0.39 1.60E-03 - -
cg10152449 CHST12 1 458 -0.68 7.47E-11 -0.54 2.56E-05 0.58 1.19E-07 0.44 2.92E-04 0.40 1.29E-03 -0.30 2.15E-02
cg02217713 PRKAR1B 1 452 -0.69 4.21E-11 -0.57 6.60E-06 0.60 3.88E-08 0.43 4.27E-04 0.33 8.85E-03 -0.26 4.66E-02
cg08122652 PARP9
DTX3L
1 430 -0.69 4.61E-11 -0.53 3.35E-05 0.55 9.54E-07 0.29 2.30E-02 0.31 1.43E-02 -0.43 7.51E-04
cg14392283 LY6E 1 301 -0.71 4.64E-12 -0.60 1.14E-06 0.48 3.23E-05 0.26 3.71E-02 0.30 1.60E-02 -0.22 -
cg11224765 ODF3B 1 231 -0.66 3.45E-10 -0.56 9.95E-06 0.43 1.95E-04 0.31 1.29E-02 0.36 3.93E-03 -0.07 -
cg08926253 IRF7 1 225 -0.68 1.12E-10 -0.52 5.66E-05 0.51 8.22E-06 0.32 1.04E-02 0.31 1.49E-02 -0.30 2.27E-02
cg21535657 ETV6 1 168 -0.66 4.48E-10 -0.38 4.70E-03 0.45 8.15E-05 0.36 3.30E-03 0.30 1.52E-02 - -
cg02679745 C9orf139
FUT7
1 148 -0.58 1.46E-07 -0.47 2.64E-04 0.47 4.25E-05 0.37 2.77E-03 0.28 2.90E-02 - -
cg01190666 PRIC285 1 126 -0.60 5.22E-08 -0.42 1.38E-03 0.48 2.22E-05 0.35 5.29E-03 0.32 1.15E-02 - -
cg22862003 MX1 1 124 -0.55 8.10E-07 -0.44 6.93E-04 0.51 8.20E-06 0.37 2.58E-03 0.37 3.14E-03 - -
cg06981309 PLSCR1 1 107 -0.61 2.10E-08 -0.51 5.90E-05 0.43 2.27E-04 0.26 4.10E-02 0.33 8.66E-03
cg02297838 MIR19A
MIR17HG
1 106 -0.64 2.00E-09 -0.52 4.05E-05 0.55 1.01E-06 0.37 2.55E-03 0.36 3.68E-03 -0.36 5.92E-03
cg01774027 ARID3A 1 95 -0.64 1.78E-09 -0.56 9.48E-06 0.61 1.95E-08 0.36 3.43E-03 0.33 7.40E-03 - -
cg20631044 C19orf54
SNRPA
1 95 -0.58 1.28E-07 -0.53 3.24E-05 0.55 7.25E-07 0.37 2.94E-03 0.27 3.15E-02 - -
cg01623438 CTSZ 1 89 -0.53 2.01E-06 -0.40 2.58E-03 0.48 3.08E-05 0.36 3.81E-03 0.32 1.12E-02 - -
cg14293575 USP18 1 78 -0.61 2.46E-08 -0.39 2.92E-03 0.41 3.73E-04 - - - - - -
cg06164260 BCL6 1 76 -0.59 9.08E-08 -0.48 1.83E-04 0.51 7.27E-06 0.34 6.43E-03 0.26 4.00E-02 -0.31 1.94E-02
cg14191134 LOC283050 1 68 -0.61 1.81E-08 -0.46 4.82E-04 0.55 6.36E-07 0.36 3.76E-03 0.30 1.80E-02 - -
cg21549285 MX1 1 67 -0.54 1.43E-06 -0.36 6.96E-03 0.49 2.03E-05 - - 0.27 3.09E-02 - -
cg15065340 TNK2 1 58 -0.52 4.35E-06 -0.33 1.39E-02 0.28 1.95E-02 - - - - - -
cg05883128 DDX60 1 45 -0.64 2.92E-09 -0.44 7.95E-04 0.41 4.86E-04 0.26 3.68E-02 0.34 6.98E-03 - -
cg03043696 GNB1 1 43 -0.44 1.21E-04 -0.36 6.44E-03 0.39 7.34E-04 - - - - -0.27 4.56E-02
cg10435235 ARHGEF7 1 42 -0.46 5.65E-05 -0.38 4.29E-03 0.46 7.08E-05 - - - - - -
cg20321801 CD81 1 27 -0.55 8.37E-07 -0.48 1.90E-04 0.55 1.05E-06 0.32 1.03E-02 - - - -
cg06872964 IFI44L 1 19 -0.50 1.31E-05 -0.37 5.13E-03 0.28 2.01E-02 - - - - - -
cg07892167 R3HCC1 1 17 -0.53 2.45E-06 -0.31 2.09E-02 0.43 2.28E-04 0.28 2.88E-02 - - - -
cg02385820 RINL 1 13 -0.41 4.10E-04 -0.32 1.79E-02 0.47 4.19E-05 - - - -
cg20939114 PITPNC1 2 607 0.52 3.62E-06 0.46 4.57E-04 -0.54 1.44E-06 -0.38 2.44E-03 -0.32 9.83E-03 - -
cg02538772 SND1 2 374 0.59 6.34E-08 0.44 6.99E-04 -0.53 3.07E-06 -0.35 5.15E-03 -0.29 1.98E-02 - -
cg15413523 TCF7 2 308 0.58 1.55E-07 0.39 3.60E-03 -0.37 1.47E-03 -0.37 3.19E-03 -0.39 1.69E-03 - -
cg20651018 CARS 2 308 0.63 3.63E-09 0.54 2.05E-05 -0.54 1.38E-06 -0.42 7.09E-04 -0.35 4.75E-03 - -
cg13015616 HFE 2 264 0.65 1.15E-09 0.52 4.18E-05 -0.55 7.32E-07 -0.43 5.12E-04 -0.34 5.96E-03 - -
cg26005232 NUDC 2 240 0.60 4.86E-08 0.49 1.23E-04 -0.54 1.59E-06 -0.48 7.14E-05 -0.46 1.45E-04 - -
cg08863939 TLK1 2 225 0.62 8.27E-09 0.61 9.40E-07 -0.63 4.96E-09 -0.47 8.41E-05 -0.43 5.14E-04 - -
cg04537602 CXCR5 2 154 0.61 2.30E-08 0.56 7.38E-06 -0.63 5.23E-09 -0.43 4.13E-04 -0.35 4.79E-03 - -
cg11477010 ANKFY1 2 141 0.63 7.14E-09 0.49 1.47E-04 -0.56 5.66E-07 -0.42 7.15E-04 -0.40 1.28E-03 - -
cg18338046 TCF7 2 90 0.59 6.20E-08 0.53 2.75E-05 -0.51 5.44E-06 -0.39 1.39E-03 -0.31 1.47E-02 - -
(Continued)
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Table 1). HIV-Low individuals showed hypermethylation of PARP9, MX1 and USP18 (Fig
3A–3C); and indeed, all these three genes were less expressed in HIV-Low compared with
HIV-High individuals (Fig 3D–3F). Thus, the observed DNA methylation patterns mediated
epigenetic control of gene expression for these lead candidates (Fig 3G–3I). For the validation
of the gene expression results and to confirm that the higher expression of these molecules was
associated with uncontrolled HIV-1 infection, mRNA levels for PARP9, MX1 and USP18 were
validated in independent cohorts of HIV-1 infected individuals. The cohorts included:
Untreated early infected individuals (Early, n = 8), Chronic Untreated individuals (Untreated,
n = 11), Chronic cART Treated individuals (Treated, n = 5) and Elite Controllers subjects (EC,
n = 12) (S2 Table). The group of natural HIV-1 controllers showed consistently significant
reductions in the expression levels of these genes compared with the rest of the studied groups
(Fig 3J–3L).
When testing for potential correlations between levels of methylation, gene expression and
viral parameters for all the individuals in the HIV-High and HIV-Low groups as well as from
independent cohorts, the methylation and mRNA levels for all three assessed genes PARP9,
MX1 and USP18, strongly correlated with pVL and proviral levels (Fig 4). These data indicate
that the differential expression levels of antiviral host factors (PARP9, USP18 and MX1)
between individuals with HIV-High and HIV-Low phenotypes are tightly related to epigenetic
mechanism and could explain the different gene expression levels observed between HIV-1
elite controllers and the rest of HIV-1 infected subjects.
Table 2. (Continued)





Proviral DNA CD4 Counts CTL Breadth CTL Magnitude nAb BaL
Rho p-value Rho p-value Rho p-value Rho p-value Rho p-value Rho p-value
cg19400179 DZIP3 2 70 0.55 1.03E-06 0.38 4.47E-03 -0.43 1.97E-04 -0.25 4.40E-02 - - - -
cg02676052 LCP2 2 69 0.44 1.44E-04 0.38 3.95E-03 -0.49 1.67E-05 -0.30 1.61E-02 - - - -
cg00808969 USP35
KCTD21
2 66 0.57 3.40E-07 0.40 2.82E-03 -0.57 2.04E-07 -0.32 1.17E-02 -0.28 2.43E-02 - -
cg13298528 CXCR5 2 60 0.62 7.94E-09 0.50 8.60E-05 -0.57 2.03E-07 -0.42 6.33E-04 -0.31 1.27E-02 - -
cg19368911 KIF26B 2 45 0.45 9.17E-05 0.32 1.91E-02 -0.48 2.94E-05 -0.37 3.10E-03 -0.34 6.26E-03 - -
cg00688810 SHBG
FXR2
2 43 0.56 4.15E-07 0.41 1.74E-03 -0.51 7.87E-06 -0.38 2.16E-03 -0.29 2.26E-02 - -
cg27519392 CHD7 2 40 0.60 5.24E-08 0.42 1.43E-03 -0.57 3.09E-07 -0.44 2.91E-04 -0.37 2.57E-03 - -
cg26567688 COL4A3BP 2 29 0.47 4.92E-05 0.36 6.53E-03 -0.55 7.26E-07 -0.38 2.34E-03 -0.34 5.98E-03 - -
cg08179431 HFE 2 27 0.60 4.49E-08 0.51 7.53E-05 -0.54 1.65E-06 -0.38 2.32E-03 -0.28 2.46E-02 - -
cg12042587 GHR 2 27 0.52 3.10E-06 0.48 2.43E-04 -0.38 1.05E-03 - - -0.27 3.46E-02 - -
cg22036538 CD27
LOC678655
2 27 0.53 2.54E-06 0.43 9.09E-04 -0.55 6.26E-07 -0.39 1.49E-03 -0.33 7.35E-03 - -
cg04858110 SCRN1 2 24 0.49 1.87E-05 0.29 3.46E-02 -0.50 8.87E-06 -0.31 1.40E-02 -0.31 1.49E-02 - -
cg12217560 TNFRSF19 2 21 0.46 7.12E-05 - - -0.56 5.11E-07 -0.33 7.89E-03 -0.26 4.06E-02 - -
cg14659511 DOCK9 2 14 0.46 5.15E-05 0.41 2.10E-03 -0.52 3.28E-06 -0.34 5.92E-03 - - - -
Rho is indicative of the Spearman’s rank correlation test. Only correlations with p-value <0.05 are shown.
Cl: Cluster.
Freq: Frequency
T cell Breadth: Number of reactive peptides measured by IFNg ELISpot assay.
T cell Magnitude: Median of SFC per 106 PBMC resulted in IFNg ELISpot assay.
nAb BaL: Neutralizing antibodies to HIV-1-BaL laboratory adapted virus strain (1/IC50 of plasma)
https://doi.org/10.1371/journal.ppat.1008678.t002
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These conclusions were further supported by the re-analysis of an open access dataset
(GSE53840, [18]). Using the same analysis approach as we did in our own data-set, this analy-
sis identified the most relevant DMPs that discriminated patients with pVL<10.000copies/ml
and pVL>10.000copies/ml, and further highlighted the relevance of PARP9 hypermethylation
in HIV control (S4 Table).
Opposite methylation patterns in interferon-related genes and T cell
response genes are associated with HIV-1 control
To have a broader overview of the impact of the epigenetic dysregulation in the context of anti-
viral and T cell differentiation pathways, all the significant DMPs (p<0.05) in the dataset were
studied. For the genes up-/downstream of the interferon signaling pathway (Fig 5A), we
observed a higher methylation level in HIV-Low individuals, and the same trend was observed
in genes of the antiviral pathway RIG-I/MDA-5 (MAVS and IRF7). On the other hand, HIV-
Low individuals showed lower methylation levels and thus potentially higher protein levels for
molecules involved in T-cell differentiation, including T follicular helper (Tfh) markers such
as CXCR5 and TCF7 (Fig 5B).
Furthermore, in HIV-Low individuals we identified a negative correlation between the
methylation levels of cg12459932 in RUNX3 and the methylation levels of the CpG positions
in CXCR5 (cg04537602 Rho = -0.56, p- value = 3.67 x 10−07 and cg04537602 Rho = -0.58, p-
value 1.07 x 10−07) and TCF7 (cg15413523 Rho = -0.27, p-value = 0.02 and cg18338046 Rho =
-0.47, p-value = 3.11 x 10−05). RUNX3 (hypermethylation in HIV-Low) is involved in Tfh dif-
ferentiation and has recently been reported to block CD8 effector T cell differentiation towards
Tfh lineage [19]. As a consequence, in HIV-Low individuals RUNX3 may be epigenetically
repressed to favor the differentiation of Tfh cells. This epigenetic mechanism could explain the
observed higher frequencies of this T-cell population in HIV-1 controllers [20].
Discussion
The main objective of the present study was to investigate the importance of epigenetic regula-
tion of host factors involved in the control of HIV-1 infection by assessing whether chronically
untreated HIV-1 infected individuals with high or low plasma viral load levels show marked
host genome DNA methylation patterns in the peripheral blood. Our data document signifi-
cant differences in epigenetic signatures on a wide range of host proteins between these groups
of patients and highlight the potential of methylome analyses to identify possible biomarkers
associated with spontaneous control of HIV-1 infection. Therefore, the association of HIV-1
infection with differential DNA methylation patterns previously reported in studies comparing
HIV+ and HIV- individuals [8,9], would extend the insights to markers and mechanisms
underlying the spontaneous capacity to control HIV-1 replication in chronic infection.
In our study, two immune response Gene Ontology (GO) categories were found to be
greatly under epigenetic regulation in untreated chronic HIV-1 disease with different virus
control. While in HIV-Low individuals the innate immunity GO category (antiviral response
Fig 3. Epigenetic regulation confirmation of selected candidates and gene expression validation in unrelated cohorts. Boxplot for PARP9 (A), MX1
(B) and USP18 (C) with the Beta-values in Y-axis and the HIV-High (n = 15) or HIV-Low (n = 31) groups in X-axis. (D-F) Boxplots of the
transcriptional levels of PARP9 (D), MX1 (E) and USP18 (F) analyzed by qRT-PCR, and represented here as the 2-ΔCT method corrected by the number
of CD4 counts in HIV-Low (n = 31) and HIV-High (n = 15). (G-I) Correlation plots, showing the inverse correlation between Beta-values of DMPs and
the corresponding gene expression level PARP9 (G), MX1 (H) and USP18 (I). (J-L) Boxplots indicating the gene expression level of PARP9 (J), MX1 (K)
and USP18 (L) in the independent cohorts of HIV-1 infection: Early (Early infected untreated individuals, n = 8), Untreated (Chronic infected untreated
individuals, n = 11), Treated (Chronic infected cART treated individuals, n = 5) and EC (Elite Controllers, n = 12). Mann Whitney test was applied for
groups’ comparisons and Spearman’s rank correlation test, for correlation analysis. In all the cases, p-values<0.05 were considered significant.
https://doi.org/10.1371/journal.ppat.1008678.g003
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Fig 4. Correlations of gene expression and methylation levels of PARP9, MX1 and USP18 with HIV viral load and proviral. (A and B) PARP9, MX1
and USP18 correlation of methylation levels (X-axis) and HIV plasma viral load (A, Y-axis) or HIV proviral levels at PBMCs (B, Y-axis) in HIV-High and
HIV-Low individuals. The different CpG positions are in different color (black and grey) and the two studied groups HIV-High and HIV-Low are
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and IFN inducible genes) was highly methylated, the GO category of adaptive immune
response (T cell activation and differentiation) was poorly methylated compared to HIV-High
individuals.
In particular, the most prominent DMPs signals detected in antiviral and interferon
response GO categories and correlated with virological parameters included: PARP9/DTX3L,
MX1, USP18, IFI44L and PLSCR1. These ISGs have been previously described to be involved
in different viral infections, including HIV-1 [21–23]. Furthermore, the epigenetic regulation
of the ISGs documented in our study, is in line with recently published data demonstrating a
differential transcriptional regulation of ISGs (e.g MX1, PARP genes and USP18 among others)
in total PBMC of HIV normal progressors compared with HIV controller phenotypes [24].
Additional confirmation of the findings also stems from the gene expression patterns in the
independent cohorts tested in our study, including treated and untreated HIV-1 infected indi-
viduals in different stages of HIV-1 infection including elite controller individuals.
The identified three genes play all a role in the interferon-mediated antiviral response:
PARP9 is increased in vitro models of HIV-1 infection [25,26] and, together with DTX3L, can
target histone H2BJ and increase the expression of interferon stimulated genes (ISGs) [27,28].
Similarly, USP18 has been described as a negative regulator of interferon response [21] and
has been associated to HIV-1 replication as well [29]. Contrary to MX2, no role as HIV-1
restriction factor has been described for MX1 [30,31]. However, three different studies associ-
ated the lower levels of MX1 expression in the chronic phase of infection with relative virus
control [24,32,33]. In line with these findings, our results further indicate that the epigenetic
repression of these ISGs may contribute to achieving a spontaneous sustained control of
HIV-1.
However, it needs to be stressed that our results identify factors and pathways involved in
viral control based on methylome analyses in total PBMC. Thus, the identified factors do not
necessarily need to have a direct impact on virus transcription in HIV-infected CD4 T cells. In
fact, it may be quite likely that the majority of the identified host immune mechanisms that are
associated with high or low viral load, and which are epigenetically controlled, originate from
cells not infected by HIV (especially also considering the small number of infected cells in the
peripheral blood). Interestingly, Morón-López et al (Morón-López et al. Abstract #228 CROI
2017), have reported full methylome data in isolated CD4 T cells from a small cohort of HIV
infected patients with different levels of virus control. These results showed hypermethylation
of USP18 in EC when compared to VC, supporting the results in our large cohort where
hypermethylation of this gene was associated with better HIV control as well. Evidently, it will
be very interesting to further define the methylome profile of this and other markers in latently
or productively infected CD4 cells and other target cells of active replication and viral reservoir
[34].
The role of activation of IFN pathways in the control of persistent HIV-1 infection is less
clear, despite the strong signals observed in our analyses. On one hand, the activation of IFN
genes in the acute phase of HIV-1 infection may benefit initial immune responses [35] and it
has indeed been associated with protection from HIV-1 acquisition in a recent systems vacci-
nology study on the RV144 vaccine clinical trial [36]. On the other hand, the IFN response
may become detrimental in the chronic phase of HIV-1 infection and has been related to poor
indicated with a triangle and a square, respectively. (C and D) Correlation of PARP9, MX1 and USP18 gene expression determined by qRT-PCR and HIV
plasma viral load (C, Y-axis) or HIV proviral levels at PBMCs (D, Y-axis). The different colors indicate the different groups of individuals including those
in unrelated cohorts (Early in purple, Untreated in orange, Treated in yellow, EC in red) and HIV-High (green) and HIV-Low (blue). Spearman’s rank
correlation test was applied for correlation analysis. In all cases, p-values<0.05 were considered significant.
https://doi.org/10.1371/journal.ppat.1008678.g004
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Fig 5. HIV-Low individuals show higher methylation levels in interferon stimulated genes and lower methylation levels in
genes related to T follicular helper (Tfh). All differentially methylated CpG positions in the dataset (p<0.05) are shown in the
context of two different pathways. A) Pathway representing genes associated with antiviral and interferon response focused on Role
of RIG-I like Receptors in Antiviral Innate Immunity, Antiviral activation of IRF by cytosolic pattern recognition receptors and
Interferon Signaling canonical pathways from IPA. B) Scheme showing T Helper Cell Differentiation canonical pathway from IPA
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antiviral response, higher virus loads and lower CD4 counts [37]. Supporting this observations,
experiments in cART treated, HIV-1 infected humanized mice also showed that the blockade
of IFNAR decreased immune activation and the size of the HIV-1 reservoir [38]. Similarly,
Non-Human Primate (NHP) models using sooty mangabeys infected with Simian immunode-
ficiency virus (SIV) demonstrated an upregulation of PARP9 and USP18 among other ISGs
that were later decreased in the chronic phase of SIV infection and, may be involved in the
reduced disease progression in these animals despite the fact that they present with unusually
high viral loads. In contrast, SIVmac239 infected Rhesus Macaques (as a model of continuing
disease progression) maintain high levels of ISGs (including MX1) in the chronic phase. This
findings derived from NHP models suggests that the downregulation of the IFN response that
may help slow disease progression after SIV infection [39]. The same conclusion may be
drawn from our dataset, where the higher methylation of ISGs and thus, lower expression lev-
els, might improve the immune control of HIV-1 by downregulating IFN signaling and avoid-
ing the systemic inflammation and consequent associated immune deterioration. Therefore,
we suggest that the observed epigenetic brake on IFN signaling pathways may play a critical
role in HIV-1 disease progression or HIV-1 control. Further analyses of individuals with
known time since infection will be needed to prove this hypothesis. Furthermore, the study of
individuals sampled before and after HIV-1 infection would also be insightful to determine
when during the HIV-1 infection these differential DNA methylation patterns are established.
Individuals that initiate cART treatment within first days or weeks after HIV-1 show a
reduced viral reservoir, but this is not enough to achieve an HIV-1 cure [40]. To date, many
eradication and cure strategies aim to reactivate the latent virus with so-called latency revers-
ing agents given in combination with therapeutic vaccines [41]. However, DNA methylation
patterns existing in treated individual might well influence the outcome of such therapeutic
interventions since our results show an epigenetic regulation of antiviral host factors and point
to a possible epigenetic regulation of T cell differentiation. In regard to the latter, the two CpG
positions identified in CXCR5 and TCF7 are of particular interest. While these genes have
been associated with T follicular helper (Tfh) phenotypes in the past [42], with our study we
now demonstrate that their expression is tightly controlled by epigenetic mechanisms and that
this regulation may impact host defense and viral replication as both CpG positions were cor-
related with the breadth and magnitude of the HIV-1-specific T-cell responses, plasma viral
load as well as the proviral levels. Furthermore, multiple DMPs were found in the Tfh pathway
(Fig 5B) suggesting the epigenetic regulation of Tfh differentiation as a mechanism that might
explain the higher frequencies of circulating Tfh in HIV-1 controllers [20]. As a consequence,
the low methylation levels of these genes and elevated gene expression in HIV-Low individu-
als, may benefit effective anti-viral immune responses by preferentially driving T-cell differen-
tiation towards a follicular-like phenotype, which in turn might avoid T-cell exhaustion of
Th1-like cells.
Finally, aside from providing insights into natural control of HIV-1 infection, these find-
ings may be of critical importance for the design and outcome of therapeutic interventions
aimed at HIV-1 cure. Since DNA methylation marks are more stable than mechanisms regu-
lating RNA expression [43], these methylation patterns may need to be restored in HIV-1
infected individuals with uncontrolled viral replication to attain sustained virus control. There
combined with reported genes associated with Tfh phenotype. Coloring is based on methylation fold-change HIV-High/HIV-Low.
Red refers to lower methylation in HIV-Low, and green higher methylation in HIV-Low. Also, pink and blue in (A) indicate the ISGs
that are induced via type I or type II interferon, respectively. Molecules selected in the multivariate are highlighted with a blue
border. Solid lines indicate direct interactions and dashed ones, indirect interactions.
https://doi.org/10.1371/journal.ppat.1008678.g005
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are rapid advances in the field of gene editing that raise the hope that such modifications could
indeed be implemented [43].
Of note, the obtained results were based on DNA methylation patterns on available dry
PBMC cell pellets and further analysis of sorted cell type populations would be necessary to
identify potential differences in cell-type specific DNA methylation patterns. At the same time,
the study of total PBMC methylome allowed the identification of the most prominent DMPs
associated with HIV control regardless of the cell subtype. Furthermore, potential bias associ-
ated with sample cell-type heterogeneity was partially overcome with a regression model
adjusted for cell type proportion estimates [9,12] and CD4 correction. The latter helped to
account for the significant differences in CD4 T cell counts in the two main comparison
groups of HIV-Low and HIV-High. Importantly though, even without applying a CD4 counts
correction, a strong selection of anti-viral and T cell response genes and the strong relevance
of DMPs in PARP9 as well as USP18 are evident (S5 Table).
Despite these potential limitations, our study conducted in a well characterized HIV-1
infection cohort combined with comprehensive virological and immune functional assess-
ments, provides clear evidence that differential epigenetic imprints on host DNA are tightly
related to innate and adaptive immune responses against HIV-1 infection and relative control
of in vivo viral replication. It will now be interesting to further our understanding of how
DNA methylation itself is regulated in HIV-1 infected individuals and how this may allow to
develop new therapeutic strategies to improve virus-specific immunity and HIV-1 cure. Fur-
thermore, while the causal relationship between the epigenetic signals and virus control
remains to be unraveled, our data show for first time that many host factors associated with
immune control of HIV infection are under global epigenetic regulation, raising potential
challenges for future cure strategies [11].
Methods
Ethics statements
The study was approved by the Comitè Ètic d’Investigació Clı́nica of Hospital Germans Trias i
Pujol (CEIC: EO-12-042) and all participants provided written informed consent.
Patients and samples
Chronic HIV-1 seropositive subjects (n = 70) were recruited at the Hospital Germans Trias i
Pujol, Badalona, Spain, and the IMPACTA clinics in Lima, Peru. Subjects with plasma viral
loads (pVL) <10,000 HIV-1 RNA copies/ml (range 25–9,999; median 2,760) in the absence of
antiretroviral treatment were defined as "HIV-Low" (n = 41), while subjects with pVL >50,000
HIV-1 RNA copies/ml (range 50,295–1,200,000; median 237,459) were defined as "HIV-High"
(n = 29) individuals (S1 Table). CD4 counts in the HIV-Low group ranged from 404–1,343
cells/mm3 (median 741) and from 11–726 cells/mm3 in the HIV-High group (median 283).
Additional unrelated cohorts (S2 Table) were used for downstream validation of identified sig-
nals including: individuals sampled in early phase of HIV-1 infection (Early, median 3 months
after seroconversion, n = 8, median viral load = 57,860), untreated individuals in chronic
phase of infection (Untreated, n = 11, 1y before cART treatment, median viral load = 13,284),
in chronic infected treated individuals (Treated, n = 5, 1y post cART initiation, undetectable
viral load) and chronically infected elite controllers (EC, n = 13, undetectable pVL, at least 1y
without treatment). For molecular assays, DNA and RNA was extracted using the QiaAmp Kit
from available dry pellet PBMCs.
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Infinium Human Methylation450 Bead Chip
Bisulfite modification of 600 ng genomic DNA was carried out with the EZ DNA Methylation Kit
(Zymo) following the manufacturer’s protocol. Next, 4 μL of bisulfite-converted DNA were used
to hybridize on Infinium HumanMethylation450 BeadChip, following Illumina Infinium HD
Methylation protocol. Chip analysis was performed using Illumina HiScan SQ fluorescent scanner
and the intensities of the images were extracted using GenomeStudio (2010.3) Methylation mod-
ule (1.8.5) software. Quality control, background correction and quantile normalization across
arrays was performed using Minfi R/Bioconductor package [44] available for Bioconductor under
the R statistical environment [45]. Methylation level (Beta-value) for each of the 485,577 CpG
positions were calculated as the ratio of methylated signal divided by the sum of methylated and
unmethylated signals plus 100. After a normalization step, probes related to X and Y chromo-
somes were removed. Function dropLociWithSnps() of Minfi R/Bioconductor package removed
all the probes associated with SNPs in the body of the probe, specifically SNPs overlapping the
CpG site and 1 or 2 bp extension from it (SBE, single base extension). Finally, the methylation
scores were corrected for batch effect by using comBat() function from sva R/Bioconductor pack-
age [46]. Data is available at GEO under the accession number GSE140800.
Definition of CpG methylation differences
A non-specific filtering was used to determine the most variable Beta-values for CpG positions
according to standard deviation [47] and finally, we kept 56,513 CpG positions as the most
variable CpG by selecting a threshold (sd > 0.47) for subsequent analysis. For the definition of
CpG methylation differences, we applied an analysis based on an approach (CPACOR, [12]),
previously used in DNA methylation studies in HIV-1 [9,48], which consists in a two-step
regression model considering different confounders (age, sex, CD4 counts, PBMC composi-
tion and technical bias) (Fig 1A). A race confounder was not applied because all patients were
of Caucasian origin. To correct for PBMC composition, the proportion of each cell type was
estimated (WBCest) from the methylation intensity values of certain probes as described by
Houseman et al. [49] and applied in function estimateCellCounts() in Minfi R/Bioconductor
package [44]. For technical bias consideration (Fig 1A), a first model was applied using the 10
principal components (PCs) on 450K array control probes as covariates (PCs 1–10) in addition
to the so-called above confounders:
Beta corrected �WBCestþ PCs 1  10þ Ageþ Sexþ CD4counts
Subsequently, a principal component analysis (PCA) was performed on the residuals of the
technical bias correction model and 5 PCs (resPCs 1–5) were used in the second regression model:
Beta corrected � YþWBCestþ PCs 1  10þ Ageþ Sexþ CD4countsþ resPCs 1  5:
In this model (Fig 1A), Y refers to the individual class, HIV-High and HIV-Low. We
selected those differential Beta-values (p< 0.05) between Y classes. The estimate of Y will
retrieve the difference of methylation between the 2 groups considering that all the other
covariates remain constant.
Functional array analyses
Gene Ontology (GO) Enrichment Analysis was performed using the ClusterProfiler package
from R/Bioconductor based on a hypergeometric test [50] in which the background were the
2649 gene-mapped DMPs. Heat-Maps (gplots R/CRAN pakage) and Hierarchical Clustering
were performed with R software. For cluster analysis on selected CpG positions for
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classification of the two comparison groups, distances among DMPs were based on correlation
values (Spearman’s Rho) and agglomeration, on average linkage method (R/CRAN package
Hmisc). The determination of the number of clusters was based on dendrogram height (h) and
using the fpc R/CRAN package to determine the robustness of each cluster and determine the
best agglomeration method. The analysis of molecule interactions was performed using Inge-
nuity Pathway Analysis Software IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis) highlighting networks and canonical pathways affected
by HIV-High and HIV-Low groups.
Proviral (Total HIV-1-1 DNA) quantification
Proviral (Total HIV-1-1 DNA) was quantified in PBMC lysates by droplet digital polymerase
chain reaction (ddPCR) in duplicate, as described previously [51]. Briefly, two different prim-
ers/probe sets annealing to the 50LTR and Gag regions, respectively, were used to circumvent
sequence mismatch in the patients’ proviruses, and the RPP30 housekeeping gene was quanti-
fied in parallel to normalize sample input. Raw ddPCR data were analyzed using the QX100
Droplet Reader and the QuantaSoft v.1.6 software (Bio-Rad).
Measurements of adaptive host immune responses to HIV-1
T cell immunity to HIV-1 was assessed in cryopreserved isolated PBMC by IFNg ELISpot assay
(1x105 PBMC/well), using a set of 410 overlapping peptides (OLPs, (18mers overlapping by 15 aa)
covering the consensus B HIV-1 viral proteome as described elsewhere [52]. The breadth (num-
ber of reactive OLP) and magnitude (spot forming cells (SFC) per 106 PBMC) were recorded.
Neutralization activity of plasma samples was evaluated using a TZM-bl neutralization assay as
described elsewhere [53,54]. Briefly, five-fold serial dilutions of plasma samples (inactivated for 1
hour at 56˚C) were incubated in 96-well plates in duplicates for 1 hour with 200 TCID50 of the
laboratory adapted viral strain HIV-1-BaL, Vesicular stomatitis virus (VSV) envelope pseudo-
typed HIV-1 was included as a control for HIV-1 unspecific neutralization. Then, 104 TZM-bl
cells were added per well and incubated for 48 hours at 37˚C and 5% CO2. Luciferase activity was
determined by luminometry using the BriteLite plus reagent (PerkinElmer) and the Fluoroskan
Ascent FL luminometer (Labsystem). The percentage of neutralization was calculated as: % Neu-
tralization = [1−(R−Rcc/Rvc)] ×100; where R = RLU (relative light units) of the tested plasma,
Rcc = RLU of cell alone and Rvc = RLU of virus alone. The IC50 (dose inducing 50% of total
inhibitory capacity) was calculated and results are shown as reciprocal dilution.
Real Time PCR
Dry cell pellets were conserved in RNAprotect Cell Reagent (Qiagen) and used for RNA
extraction (RNeasy Plus Mini Kit, Qiagen) and retro-transcription (SuperScriptIII First-Strand
Synthesis SuperMix). The cDNA was used for RT-PCR using Taqman Gene Expression Assays
for detection of: PARP9 (Hs00967084_m1), MX1(Hs00895608_m1), USP18 (Hs00276441_m1)
and Tata binding Box protein (TBP) (Hs99999910_m1) as housekeeping gene with 7500 Fast
Dx Real-Time PCR Instrument (Applied Biosystems). The relative expression was calculated
as Relative Expression = 2-ΔCT (CT = the median of crossing thresholds from 3 replicates).
Statistics
To identify robust methylation profiles in extreme outcomes of HIV control, we decided for
our initial analysis, to classify individuals in our main cohort into two comparison groups
(HIV-High and HIV-Low) rather than conducting correlation analysis with viral load as a
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continuous variable. To this end, we applied a random forest analysis to determine the most
relevant features considering the contribution of all the CpGs at the same time. This is also a
suitable approach to deal with data collinearity [55]. Accordingly, we applied a random forest
classification model based on the previously identified 2649 gene annotated DMPs with five-
fold cross validation in an iterative way (1000 iterations) with the CMA R/Bioconductor [15].
The reliability of the model to classify individuals was assessed with the area under the
curve (AUC). The output of this analysis provides a ranking of DMPs (frequency) according
to the number of times that each CpG position was selected in the random forest analyses
(AUC = 0.92). We kept those CpG sites that were selected for a minimum of 10 times. Spear-
man’s rank correlation test was used for correlations among DMPs and clinical, virological
and immunological parameters including: CD4 counts, plasma viral load, Proviral levels, T cell
responses (T cell breadth and magnitude) and plasma neutralizing antibodies (nAb) activity
against the virus strains BaL (see corresponding methods section). The correlation data among
DMPs were plotted using Circlize R/CRAN package [56]. Finally, univariate statistical analyses
for group comparisons were based on non-parametric Mann-Whitney test and p-value < 0.05
was considered statistically significant.
Supporting information
S1 Fig. Random Forest selected CpG sites correlate among them and with antiviral and
immunological parameters. Circos plot showing DMPs associated with each of the viral and
immunological parameters and their interrelation. The significant correlations (p-value <
0.05) with CpG sites and a maximum of 15 CpG sites is shown per each parameter (based on
higher Spearman’s Rho values): viral load (orange), HIV-proviral (yellow), breadth (purple)
and magnitude (green) of the virus specific T cell response and neutralizing antibody capabili-
ties against NL43 (pink) and BaL (grey). The inter-relation between the different CpG sites
methylation levels (only correlations with Spearman’s Rho> |0.6| and p-value < 0.05) are also
shown (In green there are the positive correlations, and in red, the negative ones).
(TIF)
S1 Table. Clinical information of HIV-infected individuals ND: Not determined. T cell
Breatdh: Number of reactive peptides. T cell Magnitude: Median of SFC per 106 PBMC. nAb
NL43: Neutralizing antibodies to NL43 (1/IC50 of plasma). nAb BaL: Neutralizing antibodies
to NL43 (1/IC50 of plasma). M: Male. F: Female.
(XLSX)
S2 Table. Clinical information independent cohorts Clinical information of independent
cohorts including age, sex, viral load and CD4 counts. M: Male F: Female
(XLSX)
S3 Table. Gene Enrichment Analysis S3 Table contain 2 tables (S3 Table cluster 1 and S3
Table cluster 2) with the results from the gene enrichment analysis performed using clus-
terProfiler R/Bioconductor for each of the identified clusters.
(XLSX)
S4 Table. Classificatory CpG positions into the groups of HIV-High or HIV-Low for vali-
dation dataset GSE53840. p-value: p-value of the regression model applied to determine
DMPs. CpG positions are ordered according the frequency of selection by random forest
model. HIV-High = pVL> 10.000copies/ml. HIV-Low = pVL< 10.000copies/ml.
Chr = Chromosome.
(XLSX)
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S5 Table. Classificatory CpG positions into the groups of HIV-High or HIV-Low without
CD4 counts correction (study dataset: GSE140800). p-value: Makes reference to the p-value
of the regression model (without CD4 counts correction) applied to determine DMPs. CpG
positions are ordered according the frequency of selection by random forest model. HIV-
High = pVL > 50.000copies/ml. HIV-Low = pVL < 10.000copies/ml. Chr = Chromosome.
(XLSX)
S1 Data. Excel spreadsheet with data for the different figures. Fig 1B, Fig 1C, Fig 2A, Fig 2B,
Fig 2C, Fig 2D, Fig 3A–3I, Fig 3J–3L, Fig 4A and 4B, Fig 4C and 4D and Fig 5.
(XLSX)
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transfer assay identifies humoral responses with broad neutralization activity. Vaccine. 2011 Jul 18; 29
(32):5250–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21609746 https://doi.org/10.1016/j.
vaccine.2011.05.016 PMID: 21609746
55. James G, Witten D, Hastie T, Tibshirani R. Tree-Based Methods. In: An Introduction to Statistical Learn-
ing. Springer, New York, NY; 2013. p. 303–35. Available from: http://link.springer.com/10.1007/978-1-
4614-7138-7_8
56. Gu Z, Gu L, Eils R, Schlesner M, Brors B. Circlize implements and enhances circular visualization in R.
Bioinformatics. 2014 Oct; 30(19):2811–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
24930139 https://doi.org/10.1093/bioinformatics/btu393 PMID: 24930139
PLOS PATHOGENS Epigenetic modulation of host factors in untreated HIV infection
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008678 August 6, 2020 25 / 25
